Transarterial radioembolization with yttrium ‐90 of unresectable primary hepatic malignancy in children

ConclusionTARE ‐Y90 of unresectable primary liver malignancy is both technically feasible and demonstrates an anticancer effect, and retreatment is well tolerated. TARE‐Y90 could be considered as adjunctive therapy in pediatric patients with unresectable hepatic malignancies and could be used as a bridge to su rgical resection or liver transplant. More research is required to determine the efficacy of this treatment in children and to define the clinical scenarios where benefit is likely to be optimized.

Source: Pediatric Blood and Cancer - November 8, 2018 Category: Cancer & Oncology Authors: Allison Aguado, Ross Ristagno, Alexander J. Towbin, Anita Gupta, Sinisa Haberle, Zhihua Qi, Manish N. Patel, Kamlesh U. Kukreja, Gregory M. Tiao, James I. Geller Tags: RESEARCH ARTICLE Source Type: research